You are hereJune 4, 2018
What’s the Stem Cells Buzz this Week? - LSC Pigmentation and Stemness, ASC-treatment of Rotator cuff Disease, Genome-editing of Aniridia‐related Keratopathy, and Current Understanding and Prostate CSCs!
The Stem Cells Portal brings you a roundup of some of the new and exciting stories in the ever-changing world of stem cells, regenerative medicine, and beyond!
Pigmentation and Stemness in Limbal Stem Cell Cultures
To aid in the identification of early human limbal epithelial stem cells (hLESCs), researchers from the lab of Vladimir Zachar (Aalborg University, Denmark) recently sought to assess the utility of tumor protein p63 (p63) and ATP binding cassette subfamily B member 5 (ABCB5) as markers. In a new STEM CELLS study, Liu et al. now report that p63, but not ABCB5, predicts the immaturity of hLESCs and reveal a link between stemness with pigmentation. The authors hope that these finding will aid help to enhance the ex vivo culture of hLESCs employed to treat human limbal stem cell deficiency.
Adipose-derived Stem Cell Injections for Rotator cuff Disease
A recent study led by Chris H. Jo (Seoul National University College of Medicine, Korea) aimed to discover the potential utility of intratendinous injection of autologous adipose-tissue-derived MSCs (ASCs) in patients with rotator cuff disease, a leading cause of shoulder pain. Jo et al. have now established the feasibility, safety, and effectiveness of this approach and report some evidence of tendon defect regeneration in the absence of surgical interventions. Overall, the authors of this new STEM CELLS study hope to create a paradigm shift from surgery to stem cells in patients suffering from this condition.
Genome-editing of Aniridia‐related Keratopathy and Rescue
Heterozygous PAX6 gene mutations cause the rare and progressive panocular disease congenital aniridia and the vast majority of patients also suffer from aniridia‐related keratopathy (ARK). As a means to search for effective treat ARK, researchers from the lab of Daniel Aberdam (INSERM U976, Hôpital Saint‐Louis, Paris, France) employed CRISPR/Cas9 to introduce the PAX6 mutation in patient-derived limbal stem cells (LSCs) to create a testable model. In their new STEM CELLS study, Roux et al. describe the construction of this model and identify a soluble recombinant PAX6 protein as a possible treatment.
Current Understanding on Prostate CSCs
A new review article from STEM CELLS from the lab of Anna Dubrovska aims to bring us up to date with what we currently understand regarding cancer stem cells (CSCs) in prostate cancer. Specifically, Skvortsov et al. discuss current methods for prostate CSC enrichment and analysis, the hallmarks of prostate CSC metabolism, and the role of prostate CSCs in tumor progression.
That’s a wrap for now! Please feel free to leave a comment and discuss the papers covered here on the Stem Cells Buzz. Happy reading!